<SEC-DOCUMENT>0001193125-23-228044.txt : 20230905
<SEC-HEADER>0001193125-23-228044.hdr.sgml : 20230905
<ACCEPTANCE-DATETIME>20230905061956
ACCESSION NUMBER:		0001193125-23-228044
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230905
FILED AS OF DATE:		20230905
DATE AS OF CHANGE:		20230905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		231234078

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d549603d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of
September 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="margin-top:35pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
<FONT STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In August 2023, Sanofi published the press release attached hereto as Exhibit 99.1 which is incorporated
herein by reference. </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP><U>Exhibit&nbsp;No.</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><U>Description</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d549603dex991.htm">Press Release dated August 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>, 2023:<B> </B>Sanofi announces changes to its Executive Committee </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: September&nbsp;5, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">SANOFI</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">By &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>/s/ Alexandra
Roger&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Alexandra
Roger <BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Head of Securities Law and Capital Markets</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d549603dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:14pt">Press Release</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g549603sanofi.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Sanofi announces changes to its Executive Committee </I></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Paris, August 31</B><B><SUP STYLE="font-size:75%; vertical-align:top">st</SUP></B><B>, 2023</B>. Sanofi announces the following changes to its
Executive Committee: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Houman Ashrafian</B> is appointed as <B>Head of Research</B><B></B><B>&nbsp;&amp; Development,</B> starting
September 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Madeleine Roach</B> is appointed <B>Head of Business Operations</B>, effective October 1<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP>, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Emmanuel Frenehard</B> is appointed <B>Chief Digital Officer</B>, effective immediately. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><B>Bill Sibold, </B>Head of the Specialty Care GBU will be leaving Sanofi to pursue an external opportunity. <B>Brian
Foard</B> will lead the <B>Specialty Care</B> <B>GBU ad interim, </B>effective immediately. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Houman, Madeleine and Emmanuel will
report to Sanofi&#146;s CEO, Paul Hudson, and will be based in Paris, France. Brian, also reporting to Paul Hudson, will be based in Cambridge, US. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">For the past 3 years, Sanofi has reshaped its discovery and development of therapeutics, built a robust pipeline and sharpened its research focus,
employing cutting-edge therapeutic platforms and creating a culture that responds to the urgent needs of patients. As Sanofi&#146;s new Head of Research&nbsp;&amp; Development, <B>Houman Ashrafian </B>will be responsible for bolstering the
company&#146;s strategy to develop first or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicines and growing the momentum of Sanofi&#146;s pipeline in support of its emergence as a science-driven
and innovation leader in the industry. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In this newly created role, <B>Madeleine Roach</B> will establish and lead the Business Operations Business
Unit bringing together existing business service activities and driving further expansion of centralized services into a global unit with a focus on driving efficiency and productivity to fuel business growth and Sanofi&#146;s investment in science.
This new business unit will act as an enabler and operator of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> business support capabilities across the company ensuring optimal cross-functional resource
capacity and high-quality support across Sanofi&acute;s full organization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Emmanuel Frenehard</B>, Chief Digital Officer, will lead Sanofi&#146;s
company-wide digital transformation and continue to push forward the company&#146;s digital, data and technology strategy. Building on a solid foundation of digital tools and data, creating business value, developing the acquisition of new skills
and promoting a digital and data driven culture, Emmanuel and his teams will notably support Sanofi&#146;s goal to become the first biopharma company powered by artificial intelligence at scale, to accelerate innovation for patients and healthcare
professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Paul Hudson </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Chief Executive Officer, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<I>These new appointments, a healthy mix of internal promotions and a newcomer to Sanofi, bring three highly qualified global
leaders with new insights and world-class expertise in their field. I am confident in their capacity to inspire our people, execute and deliver on our strategy and support our ambition to be an innovative, inclusive and scientifically driven
leader.</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>On the science front, we have a bold strategy of first or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicines and vaccines to fuel the growth of our company for the years to come. With almost 80 programs in clinical development and expecting to see the results
of 27 readouts of early and <FONT STYLE="white-space:nowrap">mid-stage</FONT> molecules over the next year, I am extremely pleased to see Houman Ashrafian joining our company. He brings a wealth of expertise as a scientist and in bringing high value
transformational medicines from discovery to market. With Houman&#146;s leadership and deep understanding of science, we aspire to make our R&amp;D transformation sustainable. This is what we were aiming for when we laid out our strategy in 2019.
With 5 positive read-outs in the first six months of 2023 only, including Dupixent in COPD, our commitment to Sanofi&#146;s scientifically-driven roadmap couldn&#146;t be any stronger&#148;. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Houman Ashrafian &#150; Executive Vice President, Head of R&amp;D </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Houman joins from SV Health Investors where he is Managing Partner of the global private equity and venture capital investment platform which has a
special focus on biotechnology, healthcare growth equity, and medtech. He has a robust track record in building high value, successful companies in the healthcare space, that brought transformational medicines from discovery to market: he <FONT
STYLE="white-space:nowrap">co-founded</FONT> and chaired the biotechs Alchemab Therpeutics, Dualitas, Enara Bio, Mestag Therpeutics, Sitryx and Trex Bio. He was also member of the boards of Imbria, Prilenia and Therini Bio. Previously, he was Vice
President and head of the Clinical Science Group at UCB with a main focus on precision medicine strategies and early clinical activities across the R&amp;D portfolio. He also <FONT STYLE="white-space:nowrap">co-founded</FONT> Cardiac Report, a
cardiac services company, Heart Metabolics, Catamaran Bio, as well as Weatherden, a boutique clinical consultancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Houman is an Honorary Consultant
Cardiologist at the John Radcliffe Hospital in Oxford, and a Visiting Professor at the University of Oxford in the U.K. He has received numerous prestigious awards and recognitions over the course of his career, including the Michael Davies Early
Career Award from the British Cardiovascular Society and the Schuldham Prize. Houman has a bachelor&#146;s and master&#146;s degree from the University of Cambridge (U.K) and a BM BCh and DPhil from the University of Oxford (U.K). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Houman Ashrafian </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;<I>I am extremely excited to join a company with such an extraordinary and diverse multicultural heritage and an experienced team
of drug hunters at such an important inflection point in Sanofi&#146;s ability to generate outsized value for patients. The Play to Win strategy will continue to crystallise value through what I see as a single unified R&amp;D organisation with hubs
in France/EU</I><I></I><I>&nbsp;&amp; US and sites across the world. It is a great moment to join Sanofi as the company is more than ever at the cutting edge of drug development by living its commitment to science while also evolving its data and
computational expertise to deliver better targeted medicines and vaccines to patients faster. I am fully committed to lead Sanofi&#146;s efforts to create impactful drugs ever mindful of responsibilities to sustainability and global health&#148;.
</I> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Madeleine Roach &#150; Executive Vice President, Head of Business Operations </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Madeleine joined Sanofi as Head of Internal Audit and Risk Management in 2022 from AstraZeneca, where she was Head of Global Finance Services Asia
Pacific and Global Business Services Site Lead in Malaysia, delivering a wide range of <FONT STYLE="white-space:nowrap">top-quality</FONT> business services to stakeholders across one of the most influential regions of AstraZeneca&#146;s business,
further expanding the site with the addition of <FONT STYLE="white-space:nowrap">value-add</FONT> services and digitalization capabilities, whilst attracting top talent through strong employer branding. She previously held numerous positions in
Finance and Global Business Services with </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
growing responsibilities at AstraZeneca, in Germany and the UK. Prior to AstraZeneca, she was a Manager in the Finance Advisory Services practice at KPMG and worked as a consultant in Corporate
Tax and Accounting Advisory Services at PricewaterhouseCoopers. Madeleine holds a BA (Hons) in Economics and Politics from the University of London, School of Oriental and African Studies.<B> </B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Emmanuel Frenehard &#150; Chief Digital Officer </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Emmanuel joined Sanofi three years ago as Global Head of Digital. He subsequently held the positions of Global Head - Digital GBU teams, Global Head -
Digital Products, and has also led Sanofi&#146;s Digital Accelerator and digital commerce initiatives. Prior to Sanofi, Emmanuel spent 20 years leading large global organizations as well as three years in startups. He has built and launched multiple
global digital products in support of existing and new business models. In particular, he managed iflix&#146;s explosive adoption across Southeast Asia, and led the launch of DisneyLife, Disney&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> digital subscription service in the UK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dr.<B>&nbsp;Dietmar Berger</B> who has
successfully led Sanofi&#146;s R&amp;D team <FONT STYLE="white-space:nowrap">ad-interim</FONT> over the last few months, will continue to serve as Chief Medical Officer and Global Head of Development contributing to accelerate the development of our
enhanced pipeline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Bill Sibold</B>, EVP, Head of the Specialty Care GBU, will be leaving the company to pursue a new opportunity outside Sanofi.
Bill joined Sanofi in 2011 and, since 2017 he has been leading the GBU and building Sanofi&#146;s global leadership in Specialty care, with a focus on immunology, neurology, oncology and rare&nbsp;&amp; rare blood disorders. Sanofi thanks Bill for
his great leadership and contributions and wishes him well in his future endeavors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">While an internal and external search has already started to
identify Bill&#146;s successor, <B>Brian Foard</B>, currently Head of Specialty Care North America and U.S. Country Lead, will be taking the leadership of the <B>Specialty Care GBU ad interim</B>. With more than 20 years of specialty pharmaceutical
experience, Brian joined Sanofi in 2017 and has been driving the successful launch of Dupixent in more than 50 countries across multiple indications and age groups prior to his current role. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>Pictures available upon request. </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across
some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the center of our ambitions. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sandrine
Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25 |&nbsp;<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sally Bain</B><B></B>&nbsp;|&nbsp;+ 1 617 834 6026 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>sally.bain@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Evan Berland</B>&nbsp;| +1 215 432 0234 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nicolas
Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Eva Schaefer-Jansen</B><B></B>&nbsp;|&nbsp;+ 33 7 86 80 56 39 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>eva.schaefer-jansen@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Arnaud
Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Corentine Driancourt</B><B></B>&nbsp;|&nbsp;+ 33 6 40 56 92 21 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>corentine.driancourt@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Felix
Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Tarik Elgoutni</B>| + 1 617 710 3587 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 | <FONT
STYLE="font-family:ARIAL; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sanofi Forward Looking
Statement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;,
&#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes that the expectations reflected in such forward- looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data
and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and
commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related
pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact
that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and
uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking
Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise
any forward-looking information or statements. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g549603sanofi.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549603sanofi.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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A&@!X  P!@4 -=$D&'0,/0C-  D:1C"(JCT Q0 Z@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
